Sartorius AG (XTER:SRT) EPS (Diluted) : €2.17 (TTM As of Mar. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Sartorius AG EPS (Diluted)?

Sartorius AG's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was €0.53. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €2.17.

Sartorius AG's EPS (Basic) for the three months ended in Mar. 2024 was €0.53. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was €2.17.

Sartorius AG's EPS without NRI for the three months ended in Mar. 2024 was €0.53. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was €2.17.

During the past 12 months, Sartorius AG's average EPS without NRIGrowth Rate was -73.70% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -13.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Sartorius AG's highest 3-Year average EPS without NRI Growth Rate was 92.00% per year. The lowest was -20.50% per year. And the median was 20.00% per year.

Sartorius AG EPS (Diluted) Historical Data

The historical data trend for Sartorius AG's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG EPS (Diluted) Chart

Sartorius AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

2.29

3.07

4.66

9.91

2.99

Sartorius AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															1.36	1.39	0.13	0.12	0.53

Competitive Comparison of Sartorius AG's EPS (Diluted)

For the Medical Instruments & Supplies subindustry, Sartorius AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius AG's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sartorius AG's PE Ratio falls into.

Sartorius AG EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Sartorius AG's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(205.2	-	0)	/	34.226
	=	6.00

Sartorius AG's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(36.7	-	0)	/	69.245
	=	0.53

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.17

Sartorius AG (XTER:SRT) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Sartorius AG EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Sartorius AG's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius AG (XTER:SRT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (XTER:SRT) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

SOAGY:USA SSSGY:USA SUVPF:USA SARTF:USA 1SRT3:Italy SRT3d:UK 0NIR:UK SRT3:Germany SRT3:Austria

Address

Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079

Website

https://www.sartorius.com

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.